Arena Pharma (ARNA) Tops Q1 EPS by 1c

Arena Pharma (NASDAQ: ARNA) reported Q1 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $9.02 million.

BELVIQ® (lorcaserin HCl) Update

• IMS Health estimates that approximately 121,000 prescriptions for BELVIQ were filled in the United States in the first quarter of 2016.
• Ildong Pharmaceutical Co., Ltd., estimates that approximately 2.1 million tablets of BELVIQ were prescribed in South Korea in the first quarter of 2016, which equates to approximately 34,700 one-month prescriptions.

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.

You May Also Be Interested In

• Humana soars, Alignment Healthcare sinks on Medicare rating changes
• Potential Starbucks-Chipotle merger: major opportunity or expensive distraction?
• Constellation Brands (STZ) Beats Q2 EPS by 13c, Revenue Beats, Offers Guidance